The SGLT2 Inhibitor Empagliflozin in Patients Hospitalized for Acute Heart Failure a Multinational Randomized Trial (The EMPULSE Trial)

摘要

The EMPULSE trial was a randomized, double-blind, intention-to-treat trial that screened 566 patients, hospitalized for acute heart failure (HF). It showed that empagliflozin is effective and safe in patients admitted as decompensated chronic HF or de novo HF irrespective of baseline ejection fraction (EF).